Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15954826 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL14673479 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL1535234 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL3114634 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL6444128 | 0.98 | DUT (0.37) | DUT | |
| SCHEMBL3062404 | 0.93 | DUT (0.39) | DUT | |
| SCHEMBL8063404 | 0.88 | DUT (0.43) | DUT | |
| SCHEMBL14245094 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL9007756 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL27241092 | 0.85 | DUT (0.42) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11512075-B2 | Synthesis of 20-nor-salvinorin A | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200131162-A1 | SYNTHESIS OF 20-NOR-SALVINORIN A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-30 | — | — | US | disclosed |
| EP-3483143-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2019-05-15 | — | — | EP | disclosed |
| US-9944638-B2 | Indoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND US (IE) | 2018-04-17 | — | — | US | disclosed |
| EP-0477311-A1 | NEW LEUCOTRIENE B 4? DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-04-01 | — | — | EP | disclosed |
| EP-0460032-A1 | NOVEL VITAMIN D ANALOGUES. | LEO PHARM PROD LTD (DK) | 1991-12-11 | — | — | EP | disclosed |
| WO-1991014676-A1 | NEW LEUCOTRIENE B4 DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-10-03 | — | — | WO | disclosed |
| EP-0432861-A1 | Halogenated olefines, process for the preparation thereof and their use as pesticides | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-06-19 | — | — | EP | disclosed |
| WO-1990014329-A1 | LEUKOTRIENE B4 DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-11-29 | — | — | WO | disclosed |
| EP-0399633-A1 | Leukotriene B4 derivatives, process for their preparation and their use as medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-11-28 | — | — | EP | disclosed |
| WO-1990009991-A1 | NOVEL VITAMIN D ANALOGUES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1990-09-07 | — | — | WO | disclosed |
| US-4855322-A | ANTIANDROGENS;SKIN DISORDERS | CBD CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4689349-A | Anti-tumor halo bicyclo alkanones | CBD CORPORATION (US) | 1987-08-25 | — | — | US | disclosed |
| US-4689345-A | ANTIANDROGENS | CBD CORPORATION (US) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | DUT 496/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | DUT 1595/4885 |
| US-20200131162-A1 | SYNTHESIS OF 20-NOR-SALVINORIN A | OPRK1, OPRL1, OPRD1 | DUT 3058/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | DUT 496/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | DUT 496/4885 |
| US-11512075-B2 | Synthesis of 20-nor-salvinorin A | OPRK1, OPRL1, OPRD1 | DUT 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.